Topical Agents in the Treatment of Moderate-to-Severe Psoriasis

Therapy of Moderate-to-Severe Psoriasis, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 29-52

  Callis, Kristina P ^a   Krueger, Gerald G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20444481500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14220-6     Document Type: Chapter

References (77)

1. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43(2 Pt 1): 281–285.
2. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119(12): 1198–1208.
3. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14(12): 436–441.
4. Gower WR, Jr. Mechanism of glucocorticoid action. J Fla Med Assoc 1993; 80(10): 697–700.
5. Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh) 1989; 151: 7–10; 47–52.
6. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121(1): 63–67.
7. Cornell RC. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol 1992; 31 Suppl 1: 38–40.
8. Gibson JR, Kirsch JM, Darley CR, Harvey SG, Burke CA, Hanson ME. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol 1984; 111 Suppl 27: 204–12.
9. Barry BW, Fyrand O, Woodford R, Ulshagen K, Hogstad G. Control of the bioavailability of a topical steroid; comparison of desonide creams 0.05% and 0.1% by vasoconstrictor studies and clinical trials. Clin Exp Dermatol 1987; 12(6): 406–9.
10. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967; 48(2): 181–3.
11. Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S. A doubleblind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25(6 Pt 2): 1145–8.
12. Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25(6 Pt 2): 1153–6.
13. Katz HI, Gross E, Buxman M, Prawer SE, Schwartzel EH, Gibson JR. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol 1991; 25(6 Pt 2): 1175–8.
14. Krueger GG, O’Reilly MA, Weidner M, Dromgoole SH, Killey FP. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. J Am Acad Dermatol 1998; 38(2 Pt 1): 186–90.
15. Katz HI, Hien NT, Prawer SE, Mastbaum LI, Mooney JJ, Samson CR. Superpotent topical steroid treatment of psoriasis vulgaris—clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16(4): 804–11.
16. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61(2 Suppl): 11–21.
17. Molin L, Cutler TP, Helander I, Nyfors B, Downess N. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997; 136(1): 89–93.
18. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31(5 Pt 1): 755–9.
19. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24(3): 443–7.
20. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38(8): 628–32.
21. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol 2001; 2(2): 89–92; 93.
22. Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41(5): 269–274.
23. Katz HI, Prawer SE, Mooney JJ, Samson CR. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol 1989; 20(5 Pt 1): 731–5.
24. Alani MD, Alani SD. Allergic contact dermatitis to corticosteroids. Ann Allergy 1972; 30(4): 181–5.
25. Mommers JM, van Erp PE, van De Kerkhof PC. Clobetasol under hydrocolloid occlusion in psoriasis results in a complete block of proliferation and in a rebound of lesions following discontinuation. Dermatology 1999; 199(4): 323–7.
26. Volden G, Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992; 72(1): 69–71.
27. van de Kerkhof PC, Chang A, van der Walle HB, van Vlijmen-Willems I, Boezeman JB, Huigen-Tijdink R. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Acta Derm Venereol 1994; 74(2): 143–6.
28. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3(3): 141–7.
29. Nathan AW, Rose GL. Fatal iatrogenic Cushing’s syndrome. Lancet 1979; 1(8109): 207.
30. Kubo T, Kojima A, Yamazoe S, Ueshima K, Yamamoto T, Hirasawa Y. Osteonecrosis of the femoral head that developed after long-term topical steroid application. J Orthop Sci 2001; 6(1): 92–4.
31. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975; 111(5): 581–3.
32. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976; 112(9):1245–8.
33. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999; 41(4): 546–9.
34. Smith EL, Walworth NC, Holick MF. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86(6): 709–14.
35. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984; 224(4656): 1438–40.
36. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985; 134(5): 3032–5.
37. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998; 38(6 Pt 1): 1010–1.
38. Hecker D, Worsley J, Yueh G, Lebwohl M. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 2000; 42(6): 1008–11.
39. Kragballe K. Calcipotriol for psoriasis. Lancet 1991; 337(8751): 1229–30.
40. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26(5 Pt 1): 736–43.
41. Berth-Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127(3): 266–71.
42. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35(2 Pt 1): 268–9.
43. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39(3): 447–50.
44. Singh S, Reddy DC, Pandey SS. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000; 43(1 Pt 1): 61–5.
45. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, al-Alem S, Abdulla SA. Occlusive versus nonocclusive calcipotriol ointment treatment for palmoplantar psoriasis. Int J Tissue React 2001; 23(2): 59–62.
46. Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31(1): 68–74.
47. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998; 10(2): 143–6.
48. van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138(1): 84–9.
49. Katz HI. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol 1997; 37(3 Pt 2): S62–8.
50. Ramsay CA, Schwartz BE, Lowson D, Papp K, Boldue A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000; 200(1): 17–24.
51. Koo J. Diluting Dovonex. Psoriasis Forum 1995; 1: 6.
52. Georgiou S, Tsambaos D. Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol 1999; 79(1): 86.
53. Dwyer C, Chapman RS. Calcipotriol and hypercalcaemia. Lancet 1991; 338(8769): 764–5.
54. Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebocontrolled study. Acta Derm Venereol 1993; 73(4): 300–4.
55. Chandraratna RA. Tazarotene–first of a new generation of receptor-selective retinoids. Br J Dermatol 1996; 135 Suppl 49: 18–25.
56. Duvic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998; 39(4 Pt 2): S129–33.
57. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998; 134(1): 57–60.
58. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001; 40(3): 210–2.
59. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38(5 Pt 1): 705–11.
60. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001; 40(1): 64–6.
61. Lesnik RH, Mezick JA, Capetola R, Kligman LH. Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the antiinflammatory effect. J Am Acad Dermatol 1989; 21(2 Pt 1): 186–90.
62. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45(4): 487–98; 499–502.
63. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002; 46(6): 907–13.
64. Persaud A, Bershad S, Lamba S, Lebwohl M. Short-contact tazarotene therapy for psoriasis. Poster presentation, American Academy of Dermatology, Nashville, TN, 2000.
65. Lowe NJ. Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol 1999; 140 Suppl 54: 8–11.
66. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000; 43(5 Pt 1): 821–8.
67. Behrens S, Grundmann-Kollamnn M, Schiener R, Peter RU, Kerscher M. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000; 42(3): 493–5.
68. Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999; 41(6): 927–30.
69. Klem EB. Effects of antipsoriasis drugs and metabolic inhibitors on the growth of epidermal cells in culture. J Invest Dermatol 1978; 70(1): 27–32.
70. Bonnekoh B, Bockelmann R, Ambach A, Gollnick H. Dithranol and dimethylfumarate suppress the interferon-gamma-induced up-regulation of cytokeratin 17 as a putative psoriasis autoantigen in vitro. Skin Pharmacol Appl Skin Physiol 2001; 14(4): 217–25.
71. Volden G, Bjornberg A, Tegner E, et al. Short-contact treatment at home with Micanol. Acta Derm Venereol Suppl (Stockh) 1992; 172: 20–2.
72. Goransson A. Comparison of dithranol and butantrone in short contact therapy of psoriasis. Acta Derm Venereol 1987; 67(2): 149–53.
73. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithranol in psoriasis. Preliminary report on penetration and clinical efficacy. Br J Dermatol 1980; 102(5): 571–73.
74. Statham BN, Ryatt KS, Rowell NR. Short-contact dithranol therapy–a comparison with the Ingram regime. Br J Dermatol 1984; 110(6): 703–8.
75. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000; 80(6): 451.
76. Krochmal L, Wang JC, Patel B, Rodgers J. Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol 1989; 21(5 Pt 1): 979–84.
77. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20(2): 283–91.